St. Vincent Hospital, The Catholic University of Korea | South Korea
Author Profile
Scopus
Early Academic Pursuits ✨
Prof. Jeong A Kim embarked on an illustrious academic journey in the field of medicine, laying a solid foundation at the Catholic University Medical College. She completed her premedical course in 1986, followed by earning her Doctor of Medicine degree in 1990. Her passion for internal medicine and hematology led her to pursue advanced studies at The Catholic University of Korea, where she obtained a Master’s degree in 1998 and a Ph.D. in 2001. This strong academic background established her as a dedicated scholar committed to the advancement of medical sciences.
Professional Endeavors 🏥
Prof. Kim's professional career began with rigorous postdoctoral training. She completed her internship at St. Mary’s Hospital in 1991, followed by a residency in Internal Medicine at Catholic University Medical College until 1995. She further honed her expertise in hemato-oncology through a fellowship at Samsung Medical Center. Her international exposure expanded when she joined the Department of Microbiology and Immunology at IUPUI, USA, as a postdoctoral researcher. Her academic appointments at The Catholic University of Korea saw a steady rise, from Instructor in 1997 to Assistant Professor in 2001, Associate Professor in 2009, and finally attaining the prestigious title of Professor of Internal Medicine in 2014. In parallel, she has been a dedicated physician at St. Vincent Hospital since 1997 and has been leading the hematology and stem cell transplantation center since 2018.
Contributions and Research Focus 📝
Prof. Kim has made groundbreaking contributions in hematology and oncology, with a primary focus on stem cell transplantation, multiple myeloma, and lymphoma. Her extensive clinical trials and research studies have played a pivotal role in developing new treatment modalities for hematologic malignancies. Her work in targeted therapies, chemotherapy combinations, and immunotherapy has significantly improved patient outcomes and quality of life. She has been involved in more than 60 clinical trials, evaluating novel drug efficacy and safety, including studies on Zoledronic acid for multiple myeloma, targeted treatments like Dasatinib for leukemia, and the role of rituximab in lymphoma. Her research has also delved into prognostic factors, precision medicine, and innovative therapeutic strategies for refractory and relapsed hematologic diseases.
Accolades and Recognition 🏆
Prof. Kim's relentless pursuit of excellence has earned her recognition from esteemed medical institutions and societies. As a member of the Korean Association of Internal Medicine, the Korean Hematology Association, and the American Hematology Association, she has played an instrumental role in shaping global hematologic research. Her contributions have been acknowledged through numerous awards, invitations as a keynote speaker, and influential publications in high-impact medical journals.
Impact and Influence ✨
With a career spanning decades, Prof. Kim has mentored numerous young medical professionals, guiding them in clinical research and evidence-based medical practice. Her work has directly influenced hematologic treatment protocols in Korea and internationally. Her leadership in hematology and stem cell transplantation has set new benchmarks in patient care and innovative treatment approaches.
Legacy and Future Contributions 🌟
Prof. Jeong A Kim's legacy is deeply ingrained in the advancements of hematology and oncology. Her dedication to research, patient care, and education continues to inspire the next generation of medical professionals. Looking ahead, she remains committed to pioneering more targeted therapies, enhancing stem cell transplantation techniques, and improving long-term survival rates for hematologic malignancy patients. With ongoing research and collaborations, she is poised to make even greater strides in the field, leaving an indelible mark on medical science and patient care.
Publications
📄 The presence of clonal isotype switch after autologous stem cell transplantation as a prognostic biomarker for long-term survival in patients with multiple myeloma
Authors: H. Cho, J. Kim, Y. Park, Y. Kim, J. Kim, Jeong-ah
Journal: Leukemia Research
Year: 2025
📄 Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma
Authors: N.L. Bartlett, U.H. Hahn, W. Kim, F. Jie, J. Kim, Jeong-ah
Journal: Journal of Clinical Oncology
Year: 2025
📄 Early dose reduction of dasatinib does not compromise clinical outcomes in patients with chronic myeloid leukemia: A comparative analysis of two prospective trials
Authors: D. Shin, S. Park, E. Jang, W. Lee, D. Kim
Journal: Leukemia Research
Year: 2024
📄 Geriatric risk model for older patients with diffuse large B-cell lymphoma (GERIAD): a prospective multicenter cohort study
Authors: H.Y. Yhim, Y. Park, J. Kim, Jeong-ah, D. Yang, J. Kwak
Journal: The Korean Journal of Internal Medicine
Year: 2024